Overview

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Status:
Not yet recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

OncoQuest Pharmaceuticals Inc.

Collaborator:

Veristat, LLC

Treatments:

Niraparib
Oregovomab